On October 13, Tempus AI fell 5.08% in regular trading, trading at $67.33/share, with Turnover of $138 million. Despite announcing an expansion of its multi-year collaboration with Moderna and Merck to support the potential commercialization of the individualized cancer therapy intismeran autogene, the stock remained under pressure.

The collaboration encompasses tumor tissue and blood sample collection, transfer for sequencing, and next-generation sequencing services; financial terms were not disclosed. However, intense insider selling has emerged as a near-term sentiment dampener. CEO and Chairman Eric Lefkofsky has executed multiple disposals in recent weeks, including transactions on September 17 and September 22 totaling hundreds of thousands of shares. Sector-wide weakness, with 10x Genomics down over 10%, further compounded the decline.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)